Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT – Get Free Report) was the target of a significant increase in short interest in the month of April. As of April 30th, there was short interest totaling 70,535 shares, an increase of 451.9% from the April 15th total of 12,780 shares. Based on an average trading volume of 113,858 shares, the short-interest ratio is currently 0.6 days. Approximately 0.1% of the company’s stock are sold short.
Xtant Medical Stock Performance
Shares of XTNT stock opened at $0.50 on Wednesday. Xtant Medical has a 12 month low of $0.44 and a 12 month high of $0.95. The company’s fifty day simple moving average is $0.55 and its 200-day simple moving average is $0.64. The firm has a market cap of $70.65 million, a PE ratio of 16.82 and a beta of -0.11. The company has a quick ratio of 1.63, a current ratio of 2.65 and a debt-to-equity ratio of 0.22.
Xtant Medical (NYSEAMERICAN:XTNT – Get Free Report) last released its earnings results on Tuesday, March 31st. The medical device company reported $0.03 earnings per share for the quarter. Xtant Medical had a net margin of 3.71% and a return on equity of 10.27%. The business had revenue of $32.36 million during the quarter, compared to the consensus estimate of $30.75 million.
Analyst Ratings Changes
Read Our Latest Stock Report on XTNT
Institutional Trading of Xtant Medical
Hedge funds and other institutional investors have recently modified their holdings of the stock. Jane Street Group LLC acquired a new position in shares of Xtant Medical during the 2nd quarter worth approximately $26,000. Mink Brook Asset Management LLC boosted its holdings in shares of Xtant Medical by 125.8% in the 2nd quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after buying an additional 60,997 shares during the last quarter. Tradition Wealth Management LLC bought a new position in shares of Xtant Medical in the fourth quarter valued at $79,000. Wiregrass Investment Management LLC bought a new position in shares of Xtant Medical in the fourth quarter valued at $81,000. Finally, Vanguard Group Inc. increased its holdings in Xtant Medical by 4.6% during the third quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock worth $1,529,000 after buying an additional 104,159 shares during the last quarter. Institutional investors and hedge funds own 69.33% of the company’s stock.
Xtant Medical Company Profile
Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.
The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.
Recommended Stories
- Five stocks we like better than Xtant Medical
- Navy Catalyst Ignites Odysight’s Growth Engine
- AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?
- Axon Surged After Earnings and Is Still Down Over 50% From Highs
- The Event That Could Redefine Apple’s Summer Rally
Receive News & Ratings for Xtant Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xtant Medical and related companies with MarketBeat.com's FREE daily email newsletter.
